Findings from a new large-scale clinical trial of Novo Nordisk’s weight-loss drug Wegovy suggest that it may reduce the risk of serious cardiovascular events by 20%. Advisory Board’s Regina Lohr and Gabriela Marmolejos share their three biggest takeaways from the trial and explain how these findings could impact chronic disease prevention. Wegovy may reduce the […]
